Cargando…
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers
Metastasis management remains a long-standing challenge. High abundance of E2F1 triggers tumor progression by developing protein-protein interactions (PPI) with coregulators that enhance its potential to activate a network of prometastatic transcriptional targets. Methods: To identify E2F1-coregulat...
Autores principales: | Goody, Deborah, Gupta, Shailendra K., Engelmann, David, Spitschak, Alf, Marquardt, Stephan, Mikkat, Stefan, Meier, Claudia, Hauser, Charlotte, Gundlach, Jan-Paul, Egberts, Jan-Hendrik, Martin, Hubert, Schumacher, Toni, Trauzold, Anna, Wolkenhauer, Olaf, Logotheti, Stella, Pützer, Brigitte M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401510/ https://www.ncbi.nlm.nih.gov/pubmed/30867845 http://dx.doi.org/10.7150/thno.29546 |
Ejemplares similares
-
Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures
por: Wang, Yajie, et al.
Publicado: (2016) -
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
por: Spitschak, Alf, et al.
Publicado: (2022) -
Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond
por: Logotheti, Stella, et al.
Publicado: (2021) -
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1
por: Logotheti, Stella, et al.
Publicado: (2020) -
Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures
por: Khan, Faiz M., et al.
Publicado: (2017)